Antibody drug conjugate programs (ADCs) are growing fast in oncology, combining selectivity with high potency.

Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy. Antibody-drug conjugates (ADCs) are changing ...

At World ADC London 2026, experts highlighted how advances in payload design, targeting strategies and AI-driven discovery are changing antibody-drug conjugate development.

Antibody-drug conjugates (ADCs) have reshaped the cancer treatment landscape across a variety of different tumor types. ADCs' peculiar pharmacologic design combines the cytotoxic properties of ...

ADCs have transformed bladder cancer treatment, but challenges like toxicity management and high costs remain significant hurdles. ADCs vary in components and mechanisms, influencing outcomes and ...

Stability and toxicity are two of the major challenges. First, linker stability issues result in the immediate release of the drug payload following administration, which results in persistent high ...

The clinical results from several trials suggest that patients get a high response rate from enfortumab vedotin (the antibody-drug conjugate) that is made durable from pembrolizumab (the checkpoint ...

The role of multiplexed ADCs in process control. Technical advantages of modern multiplexed ADCs. How to choose the right multiplexed ADC. Deployment tips for process-control applications. As ...